KEY FINDINGS The global antifungal drugs market is projected to develop from $12567 million in 2016 to $17428 million by 2025. Increasing awareness of the various fungal infections amid people is the prime factor up surging the antifungal drugs market globally. The market is anticipated to grow with 3.70% of CAGR throughout the forecasting period.
MARKET INSIGHTS The antifungal drugs market is segmented on the basis of drug types, therapeutic indications, applications, and geography. The antifungal drugs market on the basis of drug types is segmented into echinocandins, azoles, polyenes, allylamines, and others. On the basis of therapeutic indications, aspergillosis, dermatophytosis, candidiasis, and others. The antifungal drugs market by application is segregated into topical antifungal drugs and oral drugs. The antifungal drugs market on the basis of geography is segmented into Asia-Pacific, Europe, Rest of the World and North America. Lack of hygiene, healthcare policies and programs by the government, and advancement of drug resistance are the major drivers developing the antifungal drugs market.
REGIONAL INSIGHTS North America antifungal drugs market possesses the colossal market share in the global antifungal drugs market in 2016. A large number of people suffering from fungal infection and advancement in antifungal biopharmaceuticals in the region is up surging the growth of the antifungal market. The Asia-Pacific region is projected to be the fastest-growing region for the global antifungal drugs market. The Europe antifungal drugs market is estimated to grow during the forecast period.
COMPETITIVE INSIGHTS The leading market players for Antifungal drugs market are Vertex Pharmaceuticals, Teva Pharmaceuticals, Sanofi-Aventis, Pfizer, Novartis, Merck & Co, Kramer Laboratories, Johnson & Johnson, GlaxoSmithKline, Gilead, Bayer healthcare, Astellas Pharma Inc., Arbor Pharmaceuticals Inc., Abbott Laboratories, and 3 Baxter.
Our reports have been used by over 10K customers, including:
Vaginitis Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Vaginitis Global Clinical Trials Review, H2, 2018" provides an overview of Vaginitis clinical trials scenario.This report provides top line data relating to the clinical trials on Vaginitis. Report...
Comprehensive Pipeline Review on Ongoing Clinical and Pre-clinical studies Dermatomycoses Drug Development Pipeline Study is the latest publication from VPA Research with comprehensive information of Dermatomycoses pipeline products. The Dermatomycoses pipeline guide presents complete overview of drugs currently being developed...
KEY FINDINGS The global antifungal agents market is chiefly being propelled by factors like poor hygiene habits, supportive policies and programs by government and the development of drug resistance. By the end of the forecast period of 2018-2026, the market is likely to register a CAGR of 3.72%. MARKET INSIGHTS The...
205 pages •
By Persistence Market Research
• Jul 2018
REPORT DESCRIPTION This report examines the ‘Global Dermatophytic Onychomycosis Therapeutics Market’ for the period 2013–2026. The primary objective of the report is to offer updates and information related to opportunities in the global dermatophytic onychomycosis therapeutics market. The Dermatophytic Onychomycosis...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.